NAMPT antibody

Catalog No. ABIN615623

Product Details anti-NAMPT Antibody

Target: NAMPT (Nicotinamide phosphoribosyltransferase (NAMPT))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This NAMPT antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Specificity: Recognizes Visfatin

Purification: Affinity Chromatography employing an immobilized Human Visfatin matrix.

Immunogen: Highly pure E.coli derived recombinant Human Visfatin.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Reconstitution: Centrifuge vial prior to opening. Restore in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS, pH 7.2 without preservatives

Preservative: Without preservative

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store the lyophilized antibody at -20 °C. Following reconstitution it is stable for two weeks at 2-8 °C. Frozen aliquots are stable for 6 months when stored at -20 °C.

Expiry Date: 6 months

Target Details for NAMPT

Target: NAMPT (Nicotinamide phosphoribosyltransferase (NAMPT))

Alternative Name: Visfatin / NAMPT (NAMPT Products)

Synonyms: 1110035O14Rik antibody, PBEF antibody, PBEF1 antibody, VF antibody, VISFATIN antibody, AI314458 antibody, AI480535 antibody, NAmPRTase antibody, Pbef antibody, Pbef1 antibody, Visfatin antibody, visfatin antibody, pbef antibody, pbef1 antibody, nicotinamide phosphoribosyltransferase antibody, Nicotinamide phosphoribosyltransferase antibody, nicotinamide phosphoribosyltransferase S homeolog antibody, NAMPT antibody, Nampt antibody, nampt antibody, Smon_0680 antibody, Mrub_2845 antibody, Cseg_3704 antibody, BC1002_3997 antibody, Ftrac_2686 antibody, Varpa_5681 antibody, Celal_3900 antibody, Deima_0880 antibody, BC1001_3724 antibody, Celly_1696 antibody, Clole_1542 antibody, Tsp_05934 antibody, nampt.S antibody

Background: Visfatin, a newly identified adipocytokine ,which is predominantly secreted from visceral adipose tissue both in humans and mice . Visfatin corresponds to a protein identified previously as pre-B cell colony-enhancing factor (PBEF). Visfatin exerted insulin-mimetic effects in cultured cells, various insulin-sensitive tissues such as liver, muscle, and fat ,and lowered plasma glucose levels in mice. Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild-type littermates. visfatin binds to and activates the insulin receptor. Which may lead to new insights into glucose homeostasis and/or new therapies for metabolic disorders such as diabetes. Excess adiposity is the most important risk in the development of insulin resistance and type 2 diabetes mellitus (T2DM). Adipose tissue produces several proteins (adipocytokines) such as leptin, adiponectin, resistin, tumor necrosis factor-alpha, and IL-6, that modulate insulin sensitivity and appear to play an important role in the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, and atherosclerosis. However, the mechanisms by which fat tissue induces insulin resistance and the role of adipocytokines in the pathogenesis of T2DM have not been well established. Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is a cytokine that is highly expressed in visceral fat and was originally isolated as a secreted factor that synergizes with IL-7 and stem cell factors to promote the growth of B cell precursors. Visfatin homologs have been identified in carp, invertebrate mollusks , and bacteria, as well as in vertebrates, including humans and the mouse. It has been postulated to play a role in innate immunity. Visfatin exerts insulin-mimetic effects that are dose-dependent and quantitatively similar to those of insulin in stimulating muscle and adipocyte glucose transport, and in inhibiting hepatocyte glucose production. Intravenous injection of recombinant visfatin in mice decreased plasma glucose in a dose-dependent fashion. In keeping with its insulin-mimetic effects, visfatin was as effective as insulin in reducing hyperglycemia in insulindeficient diabetic mice. Visfatin was also found to be bound to and activate insulin receptor, causing receptor phosphorylation and the activation of downstream signaling molecules. However, visfatin and insulin did not compete for binding to the insulin receptor, indicating that the two proteins were recognized by different regions of the receptor. Thus, visfatin might play a role in glucose homeostasis and dysregulation in biosynthesis or signal transduction, and might contribute to the pathogenesis of diabetes.Synonyms: NAmPRTase, Nicotinamide phosphoribosyltransferase, PBEF, PBEF1, Pre-B-cell colony-enhancing factor 1

Gene ID: 10135

NCBI Accession: NP_005737

UniProt: P43490